Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genaissance Sees New Life For Vilazodone With Pharmacogenomics

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm licenses antidepressant from Merck KGaA after lack of efficacy in Phase II caused GlaxoSmithKline to drop project. Phase II trials to identify genetic markers of response will start in first half of 2005, with goal of developing drug/diagnostic package.

You may also be interested in...



Clinical Data CEO Drew Fromkin: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Fromkin and Chief Medical Officer Reed talk about their targeted antidepressant vilazodone and the firm’s plans for developing other drugs with companion diagnostics.

Clinical Data CEO Drew Fromkin: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Fromkin and Chief Medical Officer Reed talk about their targeted antidepressant vilazodone and the firm’s plans for developing other drugs with companion diagnostics.

Office Of Combination Products Should Coordinate, Not Review Rx/Dx Products, Roche Says

"Partner" products should be reviewed and approved by their respective division, Roche Regulatory Affairs Director Lois Hinman, PhD, says. FDA's draft guidance on co-development of drug/diagnostic products is expected by year-end. The agency is finalizing its pharmacogenomics data submission guidance.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel